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Despite the remarkable success of imatinib against Bcr-Abl, development of secondary resistance, most
often due to point mutations in the Bcr-Abl tyrosine kinase (TK) domain, is quite common. Of these, the
T315I ‘‘gatekeeper’’ mutation is resistant to all currently registered Bcr-Abl TK inhibitors (TKIs) with the
notable exception of ponatinib (IclusigTM), which was very recently approved by the United States Food
and Drug Administration (FDA). Besides ponatinib, numerous strategies have been developed to
circumvent this problem. These include the protein synthesis inhibitor omacetaxine (Synribos), and
‘‘switch-control’’ inhibitors. Dual Bcr-Abl and aurora kinase inhibitors represent another promising
strategy. Finally, several promising synergistic combinations, such as TKIs with histone deacetylase
inhibitors (HDACIs), warrant attention.
& 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
The Bcr-Abl fusion protein, central to the pathogenesis of
chronic myelogenous leukemia (CML), interacts with a variety
of effector proteins, leading to deregulated cellular proliferation,
decreased adherence of leukemia cells to the bone marrow
stroma, and a reduced apoptotic response to mutagenic stimuli.1
The revolutionary results of the International Randomized Study
of Interferon and STI571 (IRIS), a phase III randomized trial of
imatinib compared with the combination of interferon alfa and
cytarabine in newly diagnosed patients with chronic phase CML
(CML-CP), dramatically transformed the therapeutic landscape of
CML. The second generation Bcr-Abl TKIs dasatinib and nilotinib
were initially approved for CML patients intolerant of or resistant
to imatinib, and subsequently for previously untreated patients
with CML-CP. Recently, another second generation Bcr-Abl TKI,nal Medicine (Hematology/
om 234, Goodwin Research
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-NC-ND license.bosutinib (Bosulifs), has been approved for the treatment of
patients with all phases of CML who have demonstrated resis-
tance or intolerance to prior therapy.
While resistance to imatinib is rare in patients treated in CML-
CP, resistance does eventually develop in the majority of patients
treated in the advanced phases.1 In a high proportion of patients
who develop secondary resistance after initial responses, point
mutations in the BCR-ABL kinase domain have been identiﬁed,
often associated with reactivation of the dys-regulated enzymatic
activity of the Bcr-Abl protein. The ﬁrst such mutation identiﬁed
was a C-T nucleotide change that results in a threonine to
isoleucine substitution at position 315 in the Abl component of
Bcr-Abl (Thr315-Ile; T315I).2 Thr315 forms a critical hydrogen
bond with imatinib. The absence of the oxygen atom normally
provided by the side chain of Thr315 precludes formation of a
hydrogen bond with the secondary amino group of imatinib, but
does not interfere with adenosine triphosphate (ATP) binding.2
Although a large number of such mutations have now been
identiﬁed, the most important one still remains T315I, referred
to as the ‘‘gatekeeper’’ mutation, because it uniformly confers
resistance to all ﬁrst and second generation Bcr-Abl TKIs. Allo-
geneic hematopoietic stem cell transplantation (HSCT), effective
in a proportion of cases by virtue of a strong graft-versus-
leukemia (GVL) effect has, therefore, been the only recourse for
these patients.
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Ponatinib (AP24534, IclusigTM) is a multi-targeted TKI opti-
mized using structure-based drug design to bind to the inactive
conformation of Abl and AblT315I. It does not form a hydrogen
bond with the side chain of Thr315 in native Abl. The key
structural feature of the molecule is a carbon-carbon triple bond
linkage that makes productive hydrophobic contact with the side
chain of Ile315, allowing inhibition of the T315I mutant.3 In the
ongoing pivotal phase II PACE trial4 in patients with refractory
CML (all phases) and Philadelphia chromosome-positive acute
lymphoblastic leukemia (Phþ ALL) who were resistant or intol-
erant to dasatinib or nilotinib, or carried the T315I mutation, it
showed substantial activity in all patients, although activity
appeared particularly pronounced in CP patients with T315I. In
this group, at a median follow-up of 12 months, rates of CCyR and
major molecular response (MMR) were 67% and 56%, respec-
tively.4 In patients with accelerated and blastic phase CML and
Phþ ALL bearing the T315I mutation, respectively, CCyR rates
were 22%, 16% and 50%.5 Response rates continued to improve
with longer follow-up. Based on the ﬁndings of this trial, the US
FDA granted accelerated approval to ponatinib for the treatment
of adults with CML (all phases) or Phþ ALL who are resistant or
intolerant to prior TKI therapy on December 14, 2012.
Although unquestionably a major breakthrough in Bcr-Abl TKI
therapy, there have been concerns regarding the ability of
ponatinib, except at high concentrations, to inhibit compound
mutants involving T315I, such as Y253H/T315I or E255V/T315I
that sometimes pose a challenge, particularly in later lines of
therapy,3 and that it might actually be relatively less potent
against native Bcr-Abl. To answer the latter question, a phase III
trial comparing ponatinib with imatinib as initial therapy for
newly diagnosed patients with CML-CP (NCT01650805) is cur-
rently enrolling patients.Homoharringtonine/omacetaxine
Homoharringtonine is a natural alkaloid obtained from various
Cephalotaxus species that exerts antitumor activity through inhi-
bition of protein synthesis and promotion of apoptosis.6 Among
other actions, homoharringtonine down-regulates short-lived
anti-apoptotic proteins such as myeloid cell leukemia-1 (Mcl-1)
through translational inhibition. Because of its unique mechanism
of action, the activity of this agent against CML cells is indepen-
dent of their BCR-ABL mutational status. Omacetaxine mepesuc-
cinate (Synribos) is a semisynthetic form of homoharringtonine
that has excellent bioavailability upon subcutaneous administra-
tion. Although known for over three decades, the clinical devel-
opment of these compounds has been impeded by the success of
the Bcr-Abl TKIs. In a very recently reported large phase II trial7 of
omacetaxine in CML patients with T315I and TKI failure, 48 of 62
(77%) patients in CP achieved complete hematologic response
(CHR), and 10 (16%) achieved CCyR. Myelosuppression, typically
manageable by dose reduction, was the major toxicity. On
October 26, 2012, omacetaxine mepesuccinate received acceler-
ated approval from the FDA for the treatment of adults with
chronic and accelerated phase CML with resistance and/or intol-
erance to two or more TKIs.Conformational control inhibition
Conformational escape resistance is a phenomenon where
point mutations (such as T315I) drive the Abl kinase toward the
active type I state. ‘‘Switch-control inhibitors’’ bind in a non-ATP-competitive fashion to residues (E282, R386) the Abl protein uses
to switch between inactive and active conformations.8 The lead
clinical candidate, DCC-2036 (rebastinib), an orally active TKI,
potently inhibits Abl by inducing and stabilizing an inactive,
inhibitor-bound (type II) conformation, and retains efﬁcacy
against most clinically relevant CML-resistance mutants, including
T315I, although ‘‘P loop’’ mutants (E255V, E255K) may be less
sensitive. DCC-2036 inhibits Bcr-AblT315I-expressing cell lines, pro-
longs survival in mouse models of T315I-mutant CML and Phþ ALL,
and inhibits primary patient-derived leukemia cells expressing
T315I both in vitro and in vivo. Sustained inhibition of Bcr-Abl
and downstream pathways was observed in patients with refrac-
tory CML enrolled on a phase I clinical trial of this agent. In a Ba/F3
cell-based mutagenesis screen, no BCR-ABL mutations emerged at
higher concentrations of DCC-2036 that are readily achievable
clinically.8 However, rebastinib is currently being developed as
an inhibitor of the TRKA, TIE-2 and FLT3 kinases with a clinical
focus on various solid tumors and refractory acute myelogenous
leukemia.Dual aurora/BCR-ABL kinase inhibitors
The aurora kinases, which are overexpressed in many cancer
types including leukemia, are serine-threonine kinases that
regulate different steps during mitosis, including the G2-M transi-
tion, mitotic spindle organization, chromosome segregation, and
cytokinesis. MK-0457 (VX-680) and KW-2449 potently inhibit both
aurora and Bcr-Abl (including Bcr-AblT315I) kinases, but neither
compound is any longer in clinical development. Other molecules in
this category include XL228, PHA-739358, VE-465 and AT9283.
AT9283 shows potent anti-proliferative activity on BCR-ABLþ cell
lines and primary patient samples, both wild type and T315I, as
well as in mouse xenograft models.9Combination strategies
HDACIs potently enhance the lethality of the dual aurora/Bcr-
Abl TKIs by interfering with the function of chaperone proteins
such as heat shock protein 90 (hsp 90), of which Bcr-Abl is a
client, and interruption of the mitotic spindle checkpoint (induc-
tion of ‘‘mitotic slippage’’). Indeed, synergistic interactions have
been demonstrated between MK-0457 (VX-680) and vorinostat,10
as well as between KW-2449 and entinostat,11 both in vitro and in
vivo, in human BCR-ABLþ cells, including those resistant to
imatinib and bearing the T315I and E255K mutations. Accord-
ingly, a phase I clinical trial of AT9283 (which also inhibits fms-
like tyrosine kinase 3 (FLT3) and Janus kinases) and entinostat in
patients with relapsed/refractory and poor-risk acute leukemias
will soon begin enrolling patients.Conclusion
In this very brief review, an attempt has been made to
highlight some of the most promising strategies in development
against the recalcitrant T315I ‘‘gatekeeper’’ mutation in BCR-ABL.
Examples of other agents being studied include inhibitors of hsp
90 and RAC GTPases, protein phosphatase 2A activators, TKI/
farnesyltransferase inhibitor combinations, the novel TKIs
ON012380 (substrate-competitive) and HG-7-85-01 (ATP-compe-
titive), and nilotinib combined with the allosteric inhibitor GNF-2.
Although allogeneic transplantation had thus far been the only
available therapeutic option for patients with the T315I mutation,
this has ﬁnally begun to change.
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